Literature DB >> 16602327

A two-year course of specific immunotherapy or of continuous antihistamine treatment reverse eosinophilic inflammation in severe persistent allergic rhinitis.

M Lauriello1, P Muzi, L Di Rienzo, C Di Stanislao, G Coen Tirelli, M Bologna.   

Abstract

Aim of the study was to evaluate the effect of a 2-year course of subcutaneous specific immunotherapy or continuous oral antihistamine treatment on the eosinophilic inflammation in nasal secretions of patients with severe persistent allergic rhinitis caused by house dust-mites. After informed consent, 31 rhinitis patients, sensitive to dust-mite antigens, were enrolled: 12 were randomly assigned to specific immunotherapy (group A), 11 to continuous oral antihistamine (cetirizine) treatment (group B), and 8 to an oral antihistamine (cetirizine) on demand (group C). Nasal scrapings were performed with a cotton-tipped swab and cells counted before and after 24 months of therapy. Intercellular adhesion molecule-1 and eosinophil cationic protein expression in cytological smears were assessed by immuno-histochemistry. All patients completed the study. The percentage of inflammatory cell types was comparable in the 3 groups at the beginning of the study. Eosinophils, identified as cells expressing eosinophil cationic protein, significantly decreased dropping to zero after 2 years of treatment in groups A and B, while no change was observed in group C. Expression of intercellular adhesion molecule-1 also decreased significantly in groups A and B, but not in group C. This decrease was associated with a significant reduction in epithelial shedding. In the 2-year period studied, specific subcutaneous immunotherapy and continuous oral antihistamine treatment were found to be effective in reducing eosinophilic infiltration and adhesion molecule expression in the nasal mucosa of patients with persistent allergic rhinitis. Furthermore, immunotherapy was more effective in controlling epithelial disruption while antihistamines appeared to be more active in controlling nasal inflammation. Both treatments induced a significant decrease in intercellular adhesion molecule-1 expression in epithelial cells and also a dramatic reduction of eosinophil cationic protein positive staining. These parameters can be considered useful means for controlling the state of persistent inflammation which is typical of persistent respiratory allergy. Nasal scraping was demonstrated to be a simple and safe procedure for monitoring some nasal inflammation parameters.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16602327      PMCID: PMC2639903     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


  35 in total

1.  Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.

Authors:  P van Cauwenberge; C Bachert; G Passalacqua; J Bousquet; G W Canonica; S R Durham; W J Fokkens; P H Howarth; V Lund; H J Malling; N Mygind; D Passali; G K Scadding; D Y Wang
Journal:  Allergy       Date:  2000-02       Impact factor: 13.146

Review 2.  Asthma and inflammation.

Authors:  A B Kay
Journal:  J Allergy Clin Immunol       Date:  1991-05       Impact factor: 10.793

3.  Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues.

Authors:  A E Koch; J C Burrows; G K Haines; T M Carlos; J M Harlan; S J Leibovich
Journal:  Lab Invest       Date:  1991-03       Impact factor: 5.662

4.  Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, endothelial leukocyte adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease.

Authors:  L P Ruco; D Pomponi; R Pigott; A J Gearing; A Baiocchini; C D Baroni
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

5.  Possible induction of intercellular adhesion molecule-1 (ICAM-1) expression on endothelial cells by platelet-activating factor (PAF).

Authors:  J Chihara; I Maruyama; H Yasuba; A Yasukawa; T Yamamoto; D Kurachi; T Mouri; M Seguchi; S Nakajima
Journal:  J Lipid Mediat       Date:  1992 Jun-Jul

6.  Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis.

Authors:  J Knani; A Campbell; I Enander; C G Peterson; F B Michel; J Bousquet
Journal:  J Allergy Clin Immunol       Date:  1992-12       Impact factor: 10.793

7.  The expression of leukocyte-endothelial adhesion molecules is increased in perennial allergic rhinitis.

Authors:  S Montefort; I H Feather; S J Wilson; D O Haskard; T H Lee; S T Holgate; P H Howarth
Journal:  Am J Respir Cell Mol Biol       Date:  1992-10       Impact factor: 6.914

8.  Allergen-induced changes in nasal secretory responsiveness and eosinophil granulocytes.

Authors:  H Klementsson; P Venge; M Andersson; U Pipkorn
Journal:  Acta Otolaryngol       Date:  1991       Impact factor: 1.494

Review 9.  [Eosinophilic granulocytes and their significance in allergic diseases].

Authors:  P L Bruijnzeel; S Rihs; S Betz
Journal:  Schweiz Med Wochenschr       Date:  1992-02-08

10.  Eosinophil cationic protein in the nasal secretions of patients with mite allergic rhinitis.

Authors:  K Nishioka; C Saito; T Nagano; M Okano; Y Masuda; T Kuriyama
Journal:  Laryngoscope       Date:  1993-02       Impact factor: 3.325

View more
  2 in total

Review 1.  Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies.

Authors:  G W Canonica; E Compalati
Journal:  Clin Exp Immunol       Date:  2009-08-25       Impact factor: 4.330

2.  Diminished levels of nasal S100A7 (psoriasin) in seasonal allergic rhinitis: an effect mediated by Th2 cytokines.

Authors:  Anne Månsson Kvarnhammar; Camilla Rydberg; Malin Järnkrants; Mia Eriksson; Rolf Uddman; Mikael Benson; Lars-Olaf Cardell
Journal:  Respir Res       Date:  2012-01-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.